Driving Pharmaceutical Innovation
Under the leadership of Chairman and CEO Dr. Magdy Elba, APEX Pharma is driving change and innovation in Egypt and beyond.
Amid the ongoing challenges and rapid transformations in the pharmaceutical sector, Dr. Magdy Elba, Chairman and CEO of APEX Pharma, is a leader on a mission to drive fundamental and sustainable change. With strategic foresight and commitment to innovation, he has made a tangible impact on the pharmaceutical landscape in Egypt and beyond, setting a benchmark for progress in a vital industry.
Innovation and Growth
Since its establishment in 1997, APEX Pharma has pursued an ambitious vision to localize pharmaceutical manufacturing in Egypt, aligning with the country’s strategy to achieve self-sufficiency in medicine. To realize this goal, the company leverages cutting-edge technologies to deliver high-quality pharmaceutical products and has fostered a strong culture rooted in trust and lifelong learning.
This comprehensive approach has enabled APEX Pharma to navigate challenges, seize new opportunities, and drive sustainable growth in the sector while solidifying its position as one of the leading pharmaceutical firms in the Egyptian market.
Empowering People
Elba views success not as a final destination but as the beginning of a new journey of development. His leadership approach goes beyond traditional management, emphasizing the empowerment of his company’s 1,500 employees and nurturing a culture of creativity and forward-thinking. Taking a hands-on approach, he remains actively engaged with his team, ensuring success every step of the way.
An Inspirational Story
With over 35 years of experience in the pharmaceutical industry, Elba began his journey at one of Switzerland’s leading global pharmaceutical companies. This experience equipped him with the expertise and insight needed to build APEX Pharma.
Fast forward to the present, and the company’s remarkable achievements are evident in its performance. In 2024, IQVIA, a global provider of analytics, tech solutions, and clinical research services to the life sciences industry, ranked APEX Pharma fifth in the Egyptian pharmaceutical market, with a 2.9% market share and over $124 million in total sales. The company also recorded an impressive 96.4% growth rate, making it one of the fastest-growing pharmaceutical companies in Egypt.
On the manufacturing front, APEX Pharma continues to execute an ambitious expansion plan. The company is currently expanding its production facility in Egypt, with investments exceeding $59.3 million. The initiative aims to enhance production capacity and ensure a steady supply of high-quality medicines by 2028.
Regional Expansion
Elba’s ambitions extend beyond the Egyptian market to the Gulf region. APEX Pharma has secured a license to operate its factory in Saudi Arabia, strategically located in King Abdullah Economic City in Rabigh, with initial investments of $80 million. This milestone reinforces the company’s presence in the Middle East and aligns with Saudi Arabia’s Vision 2030, which prioritizes the localization of the pharmaceutical industry. The project also strengthens economic and political ties between Egypt and Saudi Arabia, fostering deeper regional integration.
Today, Dr. Magdy Elba remains a visionary leader in the pursuit of excellence. His ability to turn ambitious ideas into reality has left a lasting impact, redefining the standards of success with a singular goal: creating meaningful and lasting change.
The thoughts expressed in this advertorial are solely those of the client.